Advancements in Gastritis Treatment: Market Overview
Advancements in Gastritis Treatment: Market Overview
The gastritis treatment market comprises drugs that help in healing gastric inflammation and reducing stomach acid production. Gastritis occurs due to several factors

The gastritis treatment market comprises drugs that help in healing gastric inflammation and reducing stomach acid production. Gastritis occurs due to several factors such as excessive consumption of alcohol, infection with bacteria like H. pylori, long-term usage of painkillers like NSAIDs, and gastric disorders. The treatment options for gastritis include antacids, antibiotics, proton pump inhibitors (PPIs), and H2 blockers. Antacids provide immediate relief by neutralizing stomach acid, while PPIs and H2 blockers reduce acid production over the long term. Antibiotics are prescribed for gastritis caused due to bacterial infection. The global gastritis treatment market is estimated to be valued at US$ 131.76 billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period of 2023 to 2030.

Key Takeaways

Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. Pfizer Inc. offers antacids under the brand names Tums and Rolaids and PPIs under Nexium. AstraZeneca's pantoprazole and rabeprazole are commonly used PPIs for gastritis treatment.

The rising geriatric population prone to developing gastritis due to decreased production of stomach acid with age presents lucrative opportunities for players in the market. Various health programs aimed at detecting and eradicating H. Pylori infection can boost the demand for related drugs globally.

The major market players are focusing on expanding their presence in emerging regions of Asia Pacific, Latin America, and Middle East & Africa. Favorable reimbursement policies for gastritis drugs in developing nations will encourage the adoption of treatment regimens.

Market Drivers

Increasing prevalence of chronic gastritis: The growing prevalence of chronic gastritis conditions like atrophic gastritis that requires long-term treatment support market growth. NSAIDs usage and H. pylori infection rates are rising, leading to more gastritis cases.

Awareness about early treatment: Better awareness among people about the need for timely treatment of gastritis to prevent gastric ulcers and cancer has positively impacted the market. Primary care physicians can promptly diagnose and refer patients for appropriate therapy.

Market Restraints

Lower diagnosis and treatment rates in low-income countries: Poor economic conditions in developing regions do not allow for widespread gastritis screening and access to standard medications. The use of herbs as alternatives also restricts market demand.

Side effects of long-term PPI usage: Common side effects of prolonged usage of PPIs like diarrhea, pneumonia, bone fractures have raised safety concerns. This discourages adherence to long-term therapies.

Segment Analysis

The global gastritis treatment market is segmented on the basis of drug type, disease type, distribution channel, and region. Based on drug type, the market is divided into proton pump inhibitors, antacids, H2-receptor blockers, and others. Proton pump inhibitors sub segment dominates the market as they are highly prescribed for gastritis treatment and they have high efficiency in reducing gastric acid secretion. By disease type, the market is classified into erosive gastritis, atrophic gastritis and others. Erosive gastritis sub segment holds major share of the market as it is the most common type of gastritis. On the basis of distribution channel, hospital pharmacies, retail pharmacies, online pharmacies are included. Hospital pharmacies sub segment capture largest revenue share since prescription based drugs are preferred more for gastritis treatment by end users.

Global Analysis

Regionally, North America holds significant share in global gastritis treatment market and is expected to continue its dominance during the forecast period owing to established healthcare infrastructure and higher adoption rate of prescription drugs. Asia Pacific is fastest growing region in the market and is expected to witness notable CAGR over next few years. Rising population, expanding healthcare sector and increased health awareness among population in emerging economies such as China and India are some factors stimulating regional market growth. Additionally, growing geriatric population susceptible to gastritis diseases, increasing healthcare expenditure and rapid urbanization are also supplementing Europe gastritis treatment market growth.

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations